Dr Reddys settles litigation related to its generic buprenorphine and naloxone sublingual film
Capital MarketDr Reddys Laboratories has entered into a Settlement Agreement with Indivior Inc. and Indivior UK and Aquestive Therapeutics, Inc. (Aquestive). Pursuant to the agreement, the Company will receive payments totalling USD 72 million by 31 March 2024. The said agreement resolves all claims between the parties relating to the Company's generic buprenorphine and naloxone sublingual film, 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg dosages, including Indivior's and Aquestive's patent infringement allegations and the Company's antitrust counterclaims. As part of the settlement, the underlying litigation will be dismissed.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
